글로벌 보건

BD recognizes that existing developed world technologies do not always meet the unique healthcare demands of the developing world. As such, BD is committed to investing in new technologies that can address the specific healthcare challenges faced in the developing world.


BD has a wide variety of CD4 solutions for resource-limited settings. In 1994, the BD FACSCount™ flow cytometer was launched. The first fully automated CD4 counter expanded the test's use to patients who have high white blood cell counts, such as infants and young children.  BD recently launched the BD FACSCount CD4 reagent, which provides CD4 percentages as well as absolute counts.

To help prevent inappropriate reuse of disposable syringes and needles, BD developed several auto-disable products in close collaboration with the World Health Organization (WHO) and several other international agencies. These devices include products such as the BD SoloShot™ range of injection devices and the BD Uniject™ pre-filled injection device. To date, BD has shipped over four billion auto-disable syringes to 90 countries in Asia, Africa, Middle East, Eastern Europe, and Latin America.

The recently developed BD SoloMed™ syringe is intended for the acute-care environment in developing countries. An extra push after use breaks the plunger, preventing reuse.

BD recently launched the BD Vacutainer® CD4 stabilization blood collection tube in Africa. The tube stabilizes CD4 cells for longer time periods and at higher temperatures, enabling more samples to be taken in remote areas and transported to central labs for testing.